Singapore#s IP Office to Grant Merck#s Patent Application for CRISPR Technology

Food and Healthcare Press Releases Wednesday December 20, 2017 08:05
DARMSTADT, Germany--20 Dec--PRNewswire/InfoQuest
  • Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR
  • Fourth patent allowance for Merck's CRISPR technology; similar patents from Australian, Canadian and European Patent Offices already received
  • Merck to license its CRISPR-related patents to interested parties

Merck , a leading science and technology company, today announced that the Intellectual Property Office of Singapore has issued a "Notice of Eligibility for Grant" for Merck's patent application covering the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.

Photo - http://mma.prnewswire.com/media/620848/Merck.jpg

"Singapore's notice of patent allowance for Merck's CRISPR integration technology is yet another reinforcement of our intellectual property," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "We look forward to receiving additional grants for similar patent applications in several other countries as we collaborate with the global scientific community to find new treatments for diseases."

Merck is now licensing these foundational integration patent allowances for applications including basic science research, agricultural biotech and therapeutic use.

This forthcoming, fundamental patent in Singapore, entitled "CRISPR-BASED GENOME MODIFICATION AND REGULATION," covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging —from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

Once issued, the Singapore patent will extend the protection of Merck's CRISPR integration technology into Singapore, further strengthening the company's patent portfolio. Merck also has patent filings for its insertion CRISPR method in the U.S., Brazil, China, India, Israel, Japan and South Korea. In June 2017, Merck was awarded its first CRISPR patent by the Australian patent office. That award was followed by related patent awards by European and Canadian Patent Offices.

With a 12-year history in the genome-editing field, Merck was the first company to offer custom biomolecules for genome editing globally (TargeTron(TM) RNA-guided group II introns and CompoZr(TM) zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

Merck recognizes the potential benefits of conducting properly defined research with genome editing because of the breakthrough therapeutic potential. Therefore, Merck supports research with genome editing under careful consideration of ethical and legal standards. Merck has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Latest Press Release

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

- Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those...

The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries

Expands on existing commercial and co-development agreement for delafloxacin Consolidates company's strategic focus on infectious diseasesThe Menarini Group, an Italian biopharmaceutical company present in 136 countries worldwide, and Melinta...

Samitivej warns more Thais at risk of food allergies Failure to get treatment can cause a life-threatening reaction

According to Samitivej Allergy Institute, the number of Thais at risk from food allergies has surged by 300-400 percent in recent years as a result of lifestyle changes. The risk factors come from good living and more awareness of cleanliness, which have...

Doctors Talk: Tips to Recover from Training and Competition Like a Pro Athlete By Dr. Korakod Panich (M.D.), Herbalife Nutrition Advisory Board (NAB) Member

Doctor's Talk: Tips to Recover from Training and Competition Like a Pro Athlete By Dr. Korakod Panich (M.D.), Herbalife Nutrition Advisory Board (NAB) Member Have you ever felt that you have been exercising forever without getting anywhere near your...

Exosystems to conduct trial run of new ICT rehabilitation solution in Vietnam

The healthcare robotics company Exosystems will soon be conducting a trial run of its ICT muscular rehabilitation solution "ExoRehab" at hospitals in Vietnam. Exosystems, a member company of the K-ICT Born2Global Centre, has signed a partnership...

Related Topics